JP5685192B2 - 高尿酸血症と関連病態の治療の方法 - Google Patents

高尿酸血症と関連病態の治療の方法 Download PDF

Info

Publication number
JP5685192B2
JP5685192B2 JP2011527043A JP2011527043A JP5685192B2 JP 5685192 B2 JP5685192 B2 JP 5685192B2 JP 2011527043 A JP2011527043 A JP 2011527043A JP 2011527043 A JP2011527043 A JP 2011527043A JP 5685192 B2 JP5685192 B2 JP 5685192B2
Authority
JP
Japan
Prior art keywords
inositol
scyllo
uric acid
pharmaceutical composition
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011527043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502914A5 (https=
JP2012502914A (ja
Inventor
シダーバーム，ジェシー
Original Assignee
エラン ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー
エラン ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エラン ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー, エラン ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー filed Critical エラン ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー
Publication of JP2012502914A publication Critical patent/JP2012502914A/ja
Publication of JP2012502914A5 publication Critical patent/JP2012502914A5/ja
Application granted granted Critical
Publication of JP5685192B2 publication Critical patent/JP5685192B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011527043A 2008-09-15 2009-09-15 高尿酸血症と関連病態の治療の方法 Active JP5685192B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9702308P 2008-09-15 2008-09-15
US61/097,023 2008-09-15
PCT/US2009/056985 WO2010031051A1 (en) 2008-09-15 2009-09-15 Methods of treatment of hyperuricemia and associated disease states

Publications (3)

Publication Number Publication Date
JP2012502914A JP2012502914A (ja) 2012-02-02
JP2012502914A5 JP2012502914A5 (https=) 2012-11-08
JP5685192B2 true JP5685192B2 (ja) 2015-03-18

Family

ID=41319433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011527043A Active JP5685192B2 (ja) 2008-09-15 2009-09-15 高尿酸血症と関連病態の治療の方法

Country Status (9)

Country Link
US (1) US8748496B2 (https=)
EP (1) EP2349280B1 (https=)
JP (1) JP5685192B2 (https=)
AR (1) AR073514A1 (https=)
AU (1) AU2009290612B2 (https=)
CA (1) CA2737163C (https=)
ES (1) ES2521674T3 (https=)
TW (1) TW201016208A (https=)
WO (2) WO2010031051A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
HUE052976T2 (hu) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Urát-oxidáz variáns formái és azok alkalmazása
HUP1200205A3 (en) 2009-06-25 2012-09-28 Savient Pharmaceuticals Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
CN102726721A (zh) * 2011-12-21 2012-10-17 聂存良 一种平衡性的微量元素排铅口服液
US20160303050A1 (en) * 2015-04-20 2016-10-20 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
CN110234340A (zh) * 2016-11-11 2019-09-13 好利恩风湿病制药有限责任公司 泼尼松和尿酸酶分子的组合疗法及其用途
CN109666687B (zh) * 2018-12-14 2020-08-04 艾美科健（中国）生物医药有限公司 一种生物转化生产鲨肌醇的大肠埃希氏菌工程菌株及其构建方法和应用
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998485A (en) 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
CN103301094A (zh) * 2004-11-17 2013-09-18 乔安妮·麦克劳林 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法
JP2010514772A (ja) * 2006-12-29 2010-05-06 ノームオクシス インコーポレイテッド シクリトールおよびその誘導体ならびにその治療用途

Also Published As

Publication number Publication date
WO2010031061A1 (en) 2010-03-18
CA2737163C (en) 2019-03-12
CA2737163A1 (en) 2010-03-18
US8748496B2 (en) 2014-06-10
AU2009290612A1 (en) 2010-03-18
AR073514A1 (es) 2010-11-10
ES2521674T3 (es) 2014-11-13
EP2349280A1 (en) 2011-08-03
EP2349280B1 (en) 2014-07-30
JP2012502914A (ja) 2012-02-02
TW201016208A (en) 2010-05-01
WO2010031051A1 (en) 2010-03-18
US20100152305A1 (en) 2010-06-17
AU2009290612B2 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
JP5685192B2 (ja) 高尿酸血症と関連病態の治療の方法
JP2022020624A (ja) 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤
EP4321157B1 (en) New use of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi)
CA2907079C (en) Combination of canagliflozin and probenecid for the treatment of hyperuricemia
CN103249417A (zh) 用于治疗高尿酸血症及相关疾病的方法
TW201249432A (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
MX2015002572A (es) Combinaciones de inhibidores del cotransportador de glucosa dependiente de sodio 2 y farmacos antihipertensivos.
CA3258617A1 (en) SOLUBLE GUANYLATE CYCLASE ACTIVATORS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION IN WOMEN
US20230355618A1 (en) Raf inhibitor for treating low grade glioma
JP2011517678A (ja) 過活動膀胱の治療のためのウデナフィル、およびアルフゾシンまたはオキシブチニンの組み合わせの使用
WO2020193652A1 (en) Canagliflozin for the treatment of diabetic patients with chronic kidney disease
AU2013247291A1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
JP7668386B2 (ja) １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物
CN101229372A (zh) 一种治疗高血压的药物组合物
WO2009027577A1 (en) A combination treatment
EP4347022A1 (en) Pediatric formulations of ferric citrate
JP2006511542A (ja) バルサルタンとｃｏｘ−２インヒビターの組み合わせ
CN101370520A (zh) 用于心力衰竭的预防或治疗的医药组合物
CA3071096A1 (en) Co-administration of minocycline and colistin to reduce acute kidney injury
JP2024538054A (ja) 高シュウ酸尿症及び腎結石の治療のための１ｈ－１，２，３－トリアゾール－４－カルボン酸
JP4925406B2 (ja) 糖尿病性腎症の予防及び／又は治療剤
TW200403054A (en) Drug composition for prevention or inhibition of advance of diabetic complication
CN120379674A (zh) 脉管畸形用药物组合物及脉管畸形的治疗方法
TW201103544A (en) Pharmaceutical composition and application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140310

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150116

R150 Certificate of patent or registration of utility model

Ref document number: 5685192

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250